Avant’s Brain Cancer Vaccine Passes Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent deal with Pfizer could speed new trial, chief medical officer tells “The Pink Sheet” DAILY.
You may also be interested in...
Pfizer Taps Avant’s Phase II Brain Cancer Drug
Therapeutic vaccine is a “beautiful” match with temozolomide, Avant CEO tells “The Pink Sheet” DAILY.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.